Compositions and Methods for Suppressing Endometrial Proliferation
AssigneeRepros Therapeutics Inc.
InventorJoseph S. Podolski
Life of this patent
Estimating the term…
Loading patent…
AssigneeRepros Therapeutics Inc.
InventorJoseph S. Podolski
Estimating the term…
The subject matter of the instant invention is pertinent to the field of hormone therapy. More specifically, the subject matter of the instant invention concerns methods of treating estrogen-dependent conditions such as endometrial hyperplasia and endometrial cancer in a female undergoing estrogen and/or selective estrogen receptor modulator (SERM) therapy. The instant invention is also relevant to the suppression of endometrial proliferation. The instant invention is also relevant to the treatment of pain associated with endometriosis. The compositions for practicing the methods, comprising progesterone antagonists are also disclosed. Embodiments of the instant invention also disclose methods for identifying new selective progesterone receptor modulators for practicing disclosed methods of treatment.
A method for treating chronic estrogen-dependent hyperproliferation of uterine tissue according to an intermittent administration regimen comprising administering to a human female in need of such treatment a therapeutically effective amount of a selective progesterone receptor modulator (SPRM) for an administration period during which the SPRM is administered daily or every other day consecutively over a period of from one to six months, then discontinuing said administration for a discontinuance period by means of a continual lack of treatment for a period of time sufficient for the female to undergo menstruation, said period of time being equal to or less than the number of days during which the SPRM was previously administered, then administering a therapeutically effective amount of an SPRM daily or every other day consecutively over a period of from one to six months, then discontinuing said administration by means of continual lack of treatment for a period of time sufficient for the female to undergo menstruation, said period of time being equal to or less than the number of days during which the compound was previously administered, and repeating this pattern of administration and discontinuance of administration for a sufficient duration to treat the chronic condition.
Dependencies are inferred from the claim text.